NCT06118086 - Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Adenoid Cystic CarcinomaMetastatic Adenoid Cystic CarcinomaRecurrent Adenoid Cystic Carcinoma

Interventions

DRUG

REM-422

"* REM-422 is a first in class, small molecule mRNA inhibitor that reduces expression of the MYB transcription factor~* REM-422 will be administered orally once daily"

Trial Locations (8)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

48109

RECRUITING

University of Michigan Rogel Cancer Center, Ann Arbor

77030

RECRUITING

MD Anderson Cancer Center, Houston

94143

RECRUITING

University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco

94805

NOT_YET_RECRUITING

Institut de Cancerologie Gustave-Roussy, Villejuif

02215

RECRUITING

Dana Farber Cancer Research Institute, Boston

06189

NOT_YET_RECRUITING

Centre Antoine Lacassagne, Nice